Aptivus (Boehringer Ingelheim Pharmaceuticals, Inc.)


Welcome to the PulseAid listing for the Aptivus drug offered from Boehringer Ingelheim Pharmaceuticals, Inc.. This HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Boehringer Ingelheim Pharmaceuticals, Inc.
NON-PROPRIETARY NAME: tipranavir
SUBSTANCE NAME: TIPRANAVIR
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC]
ROUTE: ORAL
DOSAGE FORM: SOLUTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2008-09-01
END MARKETING DATE: 0000-00-00


Aptivus HUMAN PRESCRIPTION DRUG Details:

Item DescriptionAptivus from Boehringer Ingelheim Pharmaceuticals, Inc.
LABELER NAME: Boehringer Ingelheim Pharmaceuticals, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 100(mg/mL)
START MARKETING DATE: 2008-09-01
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0597-0002_6d6ce478-4464-9f6c-8933-8da6daee05fe
PRODUCT NDC: 0597-0002
APPLICATION NUMBER: NDA022292

Other TIPRANAVIR Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Boehringer Ingelheim Pharmaceuticals, Inc.Aptivus